Cost-Effectiveness of Semaglutide vs. Empagliflozin, Canagliflozin, and Sitagliptin for Treatment of Patients with Type 2 Diabetes in Denmark: A Decision-Analytic Modelling Study

OBJECTIVE: The aim was to evaluate the cost-effectiveness of oral and subcutaneous semaglutide versus other oral glucose-lowering drugs (i.e., empagliflozin, canagliflozin, and sitagliptin) for the management of type 2 diabetes (T2D) in Denmark using clinically relevant treatment intensification rul...

Descripción completa

Detalles Bibliográficos
Autores principales: Pulleyblank, Ryan, Larsen, Nikolaj Birk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333151/
https://www.ncbi.nlm.nih.gov/pubmed/37178435
http://dx.doi.org/10.1007/s41669-023-00416-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333151/
https://www.ncbi.nlm.nih.gov/pubmed/37178435
http://dx.doi.org/10.1007/s41669-023-00416-z

Ejemplares similares